How long the relief actually lasts

For most people, a course of hyaluronic acid (HA) injections into the knee provides meaningful pain relief and improved function for roughly six months. That figure comes from a 2022 systematic review of 38 randomised controlled trials involving 5,025 patients, which concluded that HA delivers adequate pain relief and functional improvement for up to six months regardless of how many injections are given or which preparation is used.

The relief is not immediate. Most patients notice a genuine difference around week four, with the effect peaking somewhere between six and eight weeks after administration. If nothing seems to have changed in the first fortnight, that is normal — HA works through gradual biological and mechanical pathways rather than producing the rapid response that a corticosteroid injection might.

Individual variation is the most important thing to understand before committing to treatment. The six-month figure is an average across a large population, not a guarantee for any one patient. In practice, some people find that the benefit fades after two months; others sustain useful relief for up to twelve months; and isolated cases in the literature describe benefit persisting for as long as three years. A 2021 comprehensive review of viscosupplementation reached similar conclusions, reinforcing both the typical duration and the breadth of individual responses.

The practical upshot: HA can offer a meaningful window of reduced pain and better function, but patients are better served by planning around a realistic range — roughly two to six months for most — rather than expecting a fixed outcome.

Who is most likely to benefit

Patient selection matters considerably, and disease severity is the most reliable guide. The clearest benefit is seen in people with Kellgren–Lawrence grades 1 to 3 — roughly mild-to-moderate joint narrowing visible on X-ray — where some cartilage cushioning remains. When the joint has reached end-stage, bone-on-bone disease, there is simply too little remaining cartilage for a lubricating injection to act upon, and clinical results reflect that: a systematic review by Nicholls et al. (2019) found that trial outcomes improved substantially when end-stage patients were excluded from the analysis.

Beyond disease grade, the typical positive-response profile looks something like this:

• Failed conservative management. Candidates who have already tried physiotherapy, weight management, and oral anti-inflammatories (NSAIDs) without sufficient relief form the core group for whom HA injections are most consistently considered.
• NSAID intolerance. Patients unable to take NSAIDs safely — due to gastrointestinal sensitivity or cardiovascular risk — represent a particularly relevant group in UK clinical practice, where long-term NSAID use carries well-recognised prescribing cautions.
• Younger or active patients. Those who wish to delay or avoid knee replacement, and who have years of activity ahead, are well-represented among patients who derive the most meaningful benefit.

One practical reason a clinician may defer or modify the plan is active joint effusion — a swollen, inflamed joint with significant excess fluid. An acutely inflamed joint tends to respond poorly; the clinician may drain the effusion first before proceeding.

Even among patients who fit this profile well, some variation in response is normal. A specialist assessment remains the only reliable way to judge individual suitability.

Why the injection takes weeks to work

The delay has a straightforward explanation rooted in how HA actually works inside the joint.

Two mechanisms are at play. The first is mechanical: in osteoarthritis, the natural hyaluronic acid in synovial fluid declines in both concentration and molecular weight, reducing its capacity to lubricate and cushion the joint. Injected HA — available in high-molecular-weight and cross-linked preparations — supplements this depleted supply. The mechanical effect is relatively immediate but modest in isolation.

The second mechanism is biological, and the more consequential of the two for sustained relief. HA interacts with receptors on joint cells to suppress pro-inflammatory signals — including prostaglandin E2 (PGE2) and NFkB — and inhibits proteases that would otherwise degrade the cartilage matrix. This anti-inflammatory cascade takes time to build, which explains both why benefit accumulates over weeks and why the effects can persist well beyond the period in which the injected HA itself remains physically present in the joint.

Whether one formulation outperforms another in a clinically meaningful way remains an open question. Current evidence, including the 2022 systematic review of 38 trials, has not established a clear hierarchy between preparations — a finding that should discourage over-interpretation of product-specific claims.

HA versus corticosteroid: the durability trade-off

Speed versus durability — that is the honest summary of this comparison, and understanding the trade-off is often what determines which injection makes more sense at a given point in a patient's journey.

Corticosteroids act quickly. Many patients notice meaningful pain reduction within days, with the effect typically established by two weeks. Hyaluronic acid, as the previous section explains, takes four weeks or more to reach useful levels of relief. For someone who needs their knee manageable ahead of a specific event, or who wants a brief pain window in which to engage with physiotherapy, corticosteroids have a practical advantage.

Beyond the first month, the picture reverses. Evidence from a direct comparison (He 2017) indicates that HA produces superior pain relief and functional improvement over the longer term — up to six months — while the effect of corticosteroids typically wanes by four to eight weeks. A 2021 comprehensive review of viscosupplementation similarly found HA more effective than corticosteroids in long-term pain reduction and restored function. Neither option is simply better; they answer different questions about timing.

One additional consideration is cartilage safety. Repeated corticosteroid injections, particularly at short intervals, raise concerns about potential cartilage degradation over time — a caution reflected in prescribing guidance that generally limits frequency of use. Hyaluronic acid does not carry an equivalent concern at standard dosing intervals.

In practice, some clinicians use both in sequence — a corticosteroid to calm an acutely symptomatic joint, followed by HA once inflammation has settled, aiming to combine near-term comfort with sustained benefit. This approach occurs clinically, though it should not be assumed as a standard protocol; individual assessment determines whether it is appropriate.

Why injection accuracy matters and what to ask your provider

Needle placement matters more than is often acknowledged. A hyaluronic acid injection that misses the joint space — landing in soft tissue rather than the synovial cavity — delivers less of the product where it needs to be, which may reduce both the degree and the duration of relief. Ultrasound guidance, where a live image is used to direct the needle accurately, significantly improves placement compared with landmark-based ('blind') technique, and evidence suggests it is associated with better clinical outcomes and longer-lasting pain relief.

Landmark-based injection remains common in GP surgeries and many NHS outpatient settings, where ultrasound equipment or trained operators may not be routinely available. In specialist musculoskeletal and sports-medicine environments, ultrasound guidance tends to be more consistently offered as standard practice.

This is worth raising directly when booking: asking whether ultrasound guidance is used as routine — rather than assuming — is a reasonable and practical step. It is not a question that implies distrust of the clinician; it is simply relevant information at the point of choosing where to have the procedure done.

Safety, guidelines, and NHS access in England

The safety record is reassuring. Post-injection flare — localised pain and swelling at the injection site — occurs in roughly 5% of cases and typically resolves within a few days without treatment. Serious adverse events are rare, and the published safety profile across large trials has been consistently good.

Guideline status is more complicated. OARSI, AAOS, and NICE all offer conditional or neutral recommendations on HA rather than clear endorsement. That ambivalence reflects the difficulty of pooling trials that used different formulations, patient populations, and outcome measures — not evidence that HA causes harm or reliably fails. Where trials have focused on well-selected patients (mild-to-moderate OA, no end-stage disease), results have been materially more consistent.

For patients in England, the practical reality is straightforward: HA is not routinely funded on the NHS, and most people who receive it do so privately. This is an access issue rather than a clinical verdict on the treatment's worth.

HA sits in a recognised clinical grey zone — widely used in musculoskeletal practice, evidence-supported in appropriate candidates, but without the clean guideline endorsement that would signal a fully settled evidence base. For patients who match the responder profile covered in earlier sections — mild-to-moderate disease, failed conservative management, no active effusion — the durability advantage over corticosteroids beyond the first month is the most clinically meaningful argument in its favour.